<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:02:20Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10393227" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10393227</identifier>
        <datestamp>2023-08-02</datestamp>
        <setSpec>jciinsight</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
              <journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
              <journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
              <journal-title-group>
                <journal-title>JCI Insight</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2379-3708</issn>
              <publisher>
                <publisher-name>American Society for Clinical Investigation</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10393227</article-id>
              <article-id pub-id-type="pmcid">PMC10393227</article-id>
              <article-id pub-id-type="pmc-uid">10393227</article-id>
              <article-id pub-id-type="pmid">37159264</article-id>
              <article-id pub-id-type="pmid">37159264</article-id>
              <article-id pub-id-type="publisher-id">167274</article-id>
              <article-id pub-id-type="doi">10.1172/jci.insight.167274</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Medicine</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahmadi</surname>
                    <given-names>Armin</given-names>
                  </name>
                  <email>arahmadi@ucdavis.edu</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-0636-8303</contrib-id>
                  <name>
                    <surname>Begue</surname>
                    <given-names>Gwenaelle</given-names>
                  </name>
                  <email>gwenaelle.begue@csus.edu</email>
                  <xref rid="A2" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-2833-6492</contrib-id>
                  <name>
                    <surname>Valencia</surname>
                    <given-names>Ana P.</given-names>
                  </name>
                  <email>apv4@uw.edu</email>
                  <xref rid="A3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-6903-6031</contrib-id>
                  <name>
                    <surname>Norman</surname>
                    <given-names>Jennifer E.</given-names>
                  </name>
                  <email>jenorman@ucdavis.edu</email>
                  <xref rid="A4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-0484-4385</contrib-id>
                  <name>
                    <surname>Lidgard</surname>
                    <given-names>Benjamin</given-names>
                  </name>
                  <email>blidgard@uw.edu</email>
                  <xref rid="A5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-0766-3195</contrib-id>
                  <name>
                    <surname>Bennett</surname>
                    <given-names>Brian J.</given-names>
                  </name>
                  <email>brian.bennett@usda.gov</email>
                  <xref rid="A6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Doren</surname>
                    <given-names>Matthew P.</given-names>
                  </name>
                  <email>mvandore@fredhutch.org</email>
                  <xref rid="A7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marcinek</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <email>dmarc@uw.edu</email>
                  <xref rid="A3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fan</surname>
                    <given-names>Sili</given-names>
                  </name>
                  <email>slfan@ucdavis.edu</email>
                  <xref rid="A8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0001-6761-5606</contrib-id>
                  <name>
                    <surname>Prince</surname>
                    <given-names>David K.</given-names>
                  </name>
                  <email>dprince3@nephrology.washington.edu</email>
                  <xref rid="A9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gamboa</surname>
                    <given-names>Jorge</given-names>
                  </name>
                  <xref rid="A10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0002-3319-1224</contrib-id>
                  <name>
                    <surname>Himmelfarb</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <email>himmej@uw.edu</email>
                  <xref rid="A9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-1571-7592</contrib-id>
                  <name>
                    <surname>de Boer</surname>
                    <given-names>Ian H.</given-names>
                  </name>
                  <email>IDeBoer@Nephrology.washington.edu</email>
                  <xref rid="A9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kestenbaum</surname>
                    <given-names>Bryan R.</given-names>
                  </name>
                  <email>brk@uw.edu</email>
                  <xref rid="A9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="true">http://orcid.org/0000-0003-1320-0442</contrib-id>
                  <name>
                    <surname>Roshanravan</surname>
                    <given-names>Baback</given-names>
                  </name>
                  <email>broshanr@ucdavis.edu</email>
                  <xref rid="A1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Department of Medicine, Division of Nephrology, UCD, Davis, California, USA.</aff>
              <aff id="A2"><label>2</label>Kinesiology Department, California State University, Sacramento, California, USA.</aff>
              <aff id="A3"><label>3</label>Department of Radiology, University of Washington, Seattle, Washington, USA.</aff>
              <aff id="A4"><label>4</label>Department of Internal Medicine, Division of Cardiovascular Medicine, UCD, Davis, California, USA.</aff>
              <aff id="A5"><label>5</label>Department of Medicine, University of Washington, Seattle, Washington, USA.</aff>
              <aff id="A6"><label>6</label>Obesity and Metabolism Research Unit, Western Human Nutrition Research Center, USDA, ARS, Davis, California, USA.</aff>
              <aff id="A7"><label>7</label>Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.</aff>
              <aff id="A8"><label>8</label>Department of Biostatistics, UCD, Davis, California, USA.</aff>
              <aff id="A9"><label>9</label>Department of Medicine, Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, Washington, USA.</aff>
              <aff id="A10"><label>10</label>School of Medicine, Vanderbilt University, Nashville, Tennessee, USA.</aff>
              <author-notes>
                <corresp>Address correspondence to: Baback Roshanravan, 451 Health Sciences Drive, Genome Biomedical Sciences Facility, Suite 5321, Davis, California 95616, USA. Phone: 530.754.8258; Email: <email>broshanr@ucdavis.edu</email>.</corresp>
              </author-notes>
              <pub-date date-type="pub" publication-format="electronic" iso-8601-date="2023-06-08T12:00:00-0400">
                <day>8</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date date-type="collection" publication-format="electronic" iso-8601-date="2023-06-08T12:00:00-0400">
                <day>8</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>8</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>8</volume>
              <issue>11</issue>
              <elocation-id>e167274</elocation-id>
              <history>
                <date date-type="received">
                  <day>21</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>3</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 Ahmadi et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Ahmadi et al.</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="https://insight.jci.org/articles/view/167274">This article is available online at https://insight.jci.org/articles/view/167274</self-uri>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Current studies suggest mitochondrial dysfunction is a major contributor to impaired physical performance and exercise intolerance in chronic kidney disease (CKD). We conducted a clinical trial of coenzyme Q10 (CoQ10) and nicotinamide riboside (NR) to determine their impact on exercise tolerance and metabolic profile in patients with CKD.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>We conducted a randomized, placebo-controlled, double-blind, crossover trial comparing CoQ10, NR, and placebo in 25 patients with an estimated glomerular filtration rate (eGFR) of less than 60mL/min/1.73 m<sup>2</sup>. Participants received NR (1,000 mg/day), CoQ10 (1,200 mg/day), or placebo for 6 weeks each. The primary outcomes were aerobic capacity measured by peak rate of oxygen consumption (VO<sub>2</sub> peak) and work efficiency measured using graded cycle ergometry testing. We performed semitargeted plasma metabolomics and lipidomics.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Participant mean age was 61.0 ± 11.6 years and mean eGFR was 36.9 ± 9.2 mL/min/1.73 m<sup>2</sup>. Compared with placebo, we found no differences in VO<sub>2</sub> peak (<italic toggle="yes">P</italic> = 0.30, 0.17), total work (<italic toggle="yes">P</italic> = 0.47, 0.77), and total work efficiency (<italic toggle="yes">P</italic> = 0.46, 0.55) after NR or CoQ10 supplementation. NR decreased submaximal VO<sub>2</sub> at 30 W (<italic toggle="yes">P</italic> = 0.03) and VO<sub>2</sub> at 60 W (<italic toggle="yes">P</italic> = 0.07) compared with placebo. No changes in eGFR were observed after NR or CoQ10 treatment (<italic toggle="yes">P</italic> = 0.14, 0.88). CoQ10 increased free fatty acids and decreased complex medium- and long-chain triglycerides. NR supplementation significantly altered TCA cycle intermediates and glutamate that were involved in reactions that exclusively use NAD<sup>+</sup> and NADP<sup>+</sup> as cofactors. NR decreased a broad range of lipid groups including triglycerides and ceramides.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Six weeks of treatment with NR or CoQ10 improved markers of systemic mitochondrial metabolism and lipid profiles but did not improve VO<sub>2</sub> peak or total work efficiency.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p>ClinicalTrials.gov NCT03579693.</p>
                </sec>
                <sec>
                  <title>Funding</title>
                  <p>National Institutes of Diabetes and Digestive and Kidney Diseases (grants R01 DK101509, R03 DK114502, R01 DK125794, and R01 DK101509). </p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <p>
                  <graphic xlink:href="jciinsight-8-167274-g302.jpg" position="float"/>
                </p>
              </abstract>
              <kwd-group kwd-group-type="specialties">
                <kwd>Clinical Trials</kwd>
                <kwd>Nephrology</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="keywords">
                <kwd>Chronic kidney disease</kwd>
                <kwd>Mitochondria</kwd>
                <kwd>Skeletal muscle</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>Introduction</title>
              <p>Patients with chronic kidney disease (CKD) suffer from a loss of functional independence and frailty (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Comorbid illnesses associated with CKD undoubtedly play a role in impaired muscle function and physical endurance (<xref rid="B3" ref-type="bibr">3</xref>). In addition, several lines of evidence suggest that kidney dysfunction itself contributes directly to a reduction in skeletal muscle function and mass (<xref rid="B4" ref-type="bibr">4</xref>). Among the mechanisms under investigation (<xref rid="B5" ref-type="bibr">5</xref>), disruption of mitochondrial oxidative capacity is considered to be a central candidate linking kidney disease with skeletal muscle impairment (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>). Interventions that target mitochondrial function in CKD have not been evaluated in human studies.</p>
              <p>Coenzyme Q10 (CoQ10) is a fat-soluble coenzyme involved in the transfer of electrons from complex I and II to complex III in the mitochondria during oxidative phosphorylation (<xref rid="B7" ref-type="bibr">7</xref>). Deficiency in CoQ10 levels has been associated with oxidative stress and impaired mitochondrial function in CKD (<xref rid="B8" ref-type="bibr">8</xref>). Plasma concentration of CoQ10 is reduced in patients with CKD compared with healthy controls (<xref rid="B9" ref-type="bibr">9</xref>); however, little is known about its treatment effects on mitochondrial metabolism, systemic inflammation, and physical performance. CoQ10 supplementation studies in aged mice have shown enhanced sirtuin 1 (SIRT1) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α )expression, leading to improved mitochondrial function and inhibition of oxidative stress (<xref rid="B10" ref-type="bibr">10</xref>). Improvements in β oxidation of fatty acids and suppressed lipid accumulation have also been reported in diabetic obese mice (<xref rid="B11" ref-type="bibr">11</xref>). Among patients with kidney failure, CoQ10 administration has been shown to reduce markers of oxidative stress (<xref rid="B9" ref-type="bibr">9</xref>).</p>
              <p>Nicotinamide riboside (NR), a precursor to NAD<sup>+</sup>, is a crucial cofactor and an electron carrier involved in oxidative metabolism, mitochondrial biogenesis, and redox homeostasis (<xref rid="B12" ref-type="bibr">12</xref>). CKD is associated with reduced NAD<sup>+</sup> biosynthesis and increased consumption limiting NAD<sup>+</sup> bioavailability (<xref rid="B13" ref-type="bibr">13</xref>). NAD<sup>+</sup> precursor supplementation may have the potential to target metabolic and clinical complications associated with CKD, including dyslipidemia, skeletal muscle dysfunction, impaired amino acid metabolism, and oxidative stress (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). Indeed, administration of NR has been shown to improve insulin sensitivity in obese mice, increase NAD<sup>+</sup> levels leading to augmented mitochondrial SIRT3 activity, and improve muscle endurance along with muscle mitochondrial content (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>). Despite the promising results from both rodent and human studies, the impact of NAD<sup>+</sup> supplements on systemic mitochondrial function and physical performance CKD are still lacking.</p>
              <p>Given the central role of mitochondrial dysfunction in the pathogenesis of kidney related skeletal muscle dysfunction (<xref rid="B18" ref-type="bibr">18</xref>), we hypothesized that therapies targeting muscle mitochondrial metabolism could improve physical endurance and systemic markers of mitochondrial metabolism in CKD. We conducted a randomized, placebo-controlled, crossover trial to test the impact of CoQ10 and NR on maximal and submaximal physical endurance capacity, work efficiency, and metabolic profiles in patients with CKD.</p>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <sec>
                <title>Participant characteristics.</title>
                <p>A total of 25 participants were enrolled and completed the study (<xref rid="sd" ref-type="sec">Supplemental Figure 1</xref>; supplemental material available online with this article; <ext-link xlink:href="https://doi.org/10.1172/jci.insight.167274DS1" ext-link-type="uri">https://doi.org/10.1172/jci.insight.167274DS1</ext-link>). The mean age of the cohort was 61.0 ± 11.6 years and 40% were female. The mean eGFR was 36.9 ± 9.2 mL/min/1.73 m<sup>2</sup>, and 16% of the participants had a diagnosis of diabetes. The median self-reported physical activity of the participants at enrollment was 13 hours per month (IQR [<xref rid="B2" ref-type="bibr">2</xref>–<xref rid="B30" ref-type="bibr">30</xref>]), and all participants had an Activities of Daily Living (ADL) score of 8 except for 1 participant with an ADL of 7. The average hemoglobin among participants was 12.7 ± 1.8 gm/dL. Characteristics of the participants in this study can be found in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
              </sec>
              <sec>
                <title>Six weeks of NR or CoQ10 treatment did not impact physical endurance and cardiorespiratory fitness outcomes compared with placebo.</title>
                <p>The mean VO<sub>2</sub> peak after placebo was 20.64 ± 4.84 mL/kg/min. Cardiorespiratory fitness (CRF) and VO<sub>2</sub> peak were not significantly different with NR and CoQ10 supplementation, with means of 21.38 ± 4.93 mL/min/kg (<italic toggle="yes">P</italic> = 0.36) and 21.41 ± 4.74 (<italic toggle="yes">P</italic> = 0.33), respectively (<xref rid="F1" ref-type="fig">Figure 1A</xref> and <xref rid="T2" ref-type="table">Table 2</xref>). Submaximal efficiency assessed by VO<sub>2</sub> at a given submaximal workload was affected by NR treatment. Mean submaximal absolute VO<sub>2</sub> after placebo was 0.70 ± 0.12 L/min at 30 W and 0.99 ± 0.12 L/min at 60 W. Compared with placebo, NR reduced submaximal absolute VO<sub>2</sub> at both 30 W to a mean of 0.67 ± 0.1 L/min (<italic toggle="yes">P</italic> = 0.03) and 60 W to a mean of 0.95 ± 0.14 L/min (<italic toggle="yes">P</italic> = 0.07) (<xref rid="F1" ref-type="fig">Figure 1, B and C</xref>, and <xref rid="T2" ref-type="table">Table 2</xref>). However, CoQ10 did not impact submaximal efficiency at 30 W and 60 W (<xref rid="F1" ref-type="fig">Figure 1, B and C</xref>, and <xref rid="T2" ref-type="table">Table 2</xref>). Mean duration of cycle ergometry after NR and CoQ10 supplementation was 982 ± 317 and 1,012 ± 332, respectively, compared with 1,009 ± 332 seconds with placebo (<xref rid="F1" ref-type="fig">Figure 1D</xref> and <xref rid="T2" ref-type="table">Table 2</xref>). Physical endurance measured as total work performed during cycle ergometry did not change after NR, with a mean of 57.72 ± 37.29 kJ (<italic toggle="yes">P</italic> = 0.47) and after CoQ10 with a mean of 61.5 ± 38.35 (<italic toggle="yes">P</italic> = 0.77) compared with placebo with a mean of 60.32 ± 39.06 (<xref rid="F1" ref-type="fig">Figure 1E</xref> and <xref rid="T2" ref-type="table">Table 2</xref>). NR and CoQ10 supplementation did not have an impact on total work efficiency, with means of 30.9 ± 18.1 kJ/(L/min) (<italic toggle="yes">P</italic> = 0.46) and 33.3 ± 15.7 (<italic toggle="yes">P</italic> = 0.55) compared with placebo with a mean of 32.2 ± 17.5 (<xref rid="F1" ref-type="fig">Figure 1F</xref> and <xref rid="T2" ref-type="table">Table 2</xref>). There were no alterations in fuel utilization at rest indicated by no change in respiratory exchange ratio (RER) at rest (<italic toggle="yes">P =</italic> 0.41 and 0.62) and VO<sub>2</sub> max (<italic toggle="yes">P</italic> = 0.44 and 0.87) after NR and CoQ10. However, RER at 30 W and 60 W were increased after NR (<italic toggle="yes">P =</italic> 0.06 and 0.04) compared with placebo (<xref rid="T2" ref-type="table">Table 2</xref>). CoQ10 did not have an impact on RER at 30 W or 60 W compared with placebo (<italic toggle="yes">P</italic> = 0.24 and 0.18) (<xref rid="T2" ref-type="table">Table 2</xref>). Estimates of differences in physical endurance outcomes, BP, and BW changes comparing NR and CoQ10 to placebo are shown in <xref rid="sd" ref-type="sec">Supplemental Table 1</xref>. Analyses of treatment by study period revealed no evidence for carryover effects among the study interventions.</p>
                <p>In the subgroup analysis, CRF (relative VO<sub>2</sub> peak, mL/kg/min) was higher and RER at 60 W was significantly lower among participants classified as active versus sedentary and good versus poor performers (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, A–D). However, we found no evidence for an impact of NR or CoQ10 on CRF or physical endurance (total work and work efficiency) in these subgroups (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, A and B). Similarly, we found no meaningful or significant impact of NR or CoQ10 supplementation on RER at 60 W in our subgroup analysis (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, C and D). Gender-stratified analysis showed no differential improvements in VO<sub>2</sub> peak and RER at 60 W among males and females (<xref rid="sd" ref-type="sec">Supplemental Figure 2</xref>, E and F).</p>
              </sec>
              <sec>
                <title>NR or CoQ10 treatment did not change kidney function and inflammatory biomarkers compared with placebo.</title>
                <p>Over the 6-week treatment period, we found no meaningful or significant change in BW (<xref rid="sd" ref-type="sec">Supplemental Table 1</xref>) or serum triglyceride associated with NR and CoQ10 supplementation compared with placebo (<italic toggle="yes">P =</italic> 0.51 and 0.69, and <italic toggle="yes">P =</italic> 0.71 and 0.70, respectively). We found no meaningful or statistically significant differences in the urine albumin-to-creatinine ratio (UACR) (P = 0.28 and 0.21) (<xref rid="sd" ref-type="sec">Supplemental Figure 3A</xref>), kidney function biomarkers, including serum creatinine (<italic toggle="yes">P =</italic> 0.23 and 0.58) and cystatin C (<italic toggle="yes">P =</italic> 0.08 and 0.87) (<xref rid="sd" ref-type="sec">Supplemental Figure 3</xref>, B and C), and inflammatory biomarker serum C-reactive protein (CRP) (<italic toggle="yes">P</italic> = 0.21 and 0.12) (<xref rid="sd" ref-type="sec">Supplemental Figure 3D</xref>) after NR and CoQ10, respectively.</p>
              </sec>
              <sec>
                <title>CoQ10 supplementation increased plasma free fatty acid and decreased triglycerides.</title>
                <p>Three of the 98 tested plasma metabolites decreased in response to CoQ10 treatment compared with placebo at the 0.05 significance level: β-alanine, lactate, and 2-deoxytetronic acid with fold changes of 0.49 (<italic toggle="yes">P</italic> = 0.01), 0.72 (<italic toggle="yes">P</italic> = 0.02), and 0.79 (<italic toggle="yes">P</italic> = 0.03), respectively (data not shown). In contrast, CoQ10 had an impact on the plasma lipid profile, altering 6% (24/394) of the detected lipid species compared with placebo (<xref rid="sd" ref-type="sec">Supplemental Table 2</xref>). These changes predominantly involved free fatty acids (FFAs) (8/24) and triglycerides (7/24). All of the altered FFAs were increased compared with placebo, ranging from an increase of 19% to 40%. Triglycerides showed the opposite pattern with a systematic decrease compared with placebo, ranging from a decrease of 19% to 66% (<xref rid="sd" ref-type="sec">Supplemental Table 2</xref>). The altered triglycerides tended to be long chained with a high degree of unsaturation. Plasma 3-hydroxybutarate was increased (not significantly), with a fold change of 1.41 (<italic toggle="yes">P</italic> = 0.07) compared with placebo (data not shown).</p>
              </sec>
              <sec>
                <title>NR treatment altered NAD<sup>+</sup>-dependent TCA cycle intermediates while decreasing plasma triglycerides and ceramides.</title>
                <p>Compared with placebo, NR supplementation altered 6% (6/98) of the detected metabolites (<xref rid="T3" ref-type="table">Table 3</xref>). These metabolites included 3 a priori–targeted TCA cycle intermediates: isocitrate, α-ketoglutarate, and malate, which all are involved in reactions that use NAD<sup>+</sup> as a cofactor. We found a significant decrease in all 3 TCA cycle intermediates compared with placebo (<xref rid="T3" ref-type="table">Table 3</xref>). In addition, glutamate, a precursor to α-ketoglutarate that feeds into the TCA cycle using NADP<sup>+</sup> as a cofactor, was increased compared with placebo (<xref rid="T3" ref-type="table">Table 3</xref>). We confirmed a small to medium magnitude of difference on TCA cycle intermediates with effect sizes ranging from –0.37 (95% CI –0.06 to –0.62) (malate) to –0.40 (95% CI 0.1 to –0.71) (isocitrate) after NR supplementation (<xref rid="T3" ref-type="table">Table 3</xref>).</p>
                <p>NR supplementation also had a meaningful impact on the lipid profile, significantly altering 7.5% (30/394) of detected lipid species (<xref rid="sd" ref-type="sec">Supplemental Table 3</xref>). Lipid species were generally decreased with 26 out of 30 altered lipids reduced compared with placebo. We found a significant decrease in all 10 altered triglycerides. These triglycerides tended to be medium chained with a lower degree of unsaturation (<xref rid="sd" ref-type="sec">Supplemental Table 3</xref>). The largest decrease was detected in triglyceride 50:0 with a 52% reduction compared with placebo. Reductions in ceramides, lyso-phosphatidylethanolamine (LPE), lyso-phosphatidylcholines (LPC), and phosphatidylethanolamines (PE) were also detected compared with placebo (<xref rid="sd" ref-type="sec">Supplemental Table 3</xref>).</p>
              </sec>
              <sec>
                <title>Six weeks of CoQ10 or NR supplementation was associated with significant alterations in plasma fatty acyls (fatty acids), glycerolipids (triglycerides and diacylglycerides), glycerophospholipids (PEs, LPEs, LPCs, and PCs), and sphingolipids (ceramides and glucosylceramides).</title>
                <p>To investigate systemic plasma lipid profile changes in response to NR and CoQ10, we assessed compositional changes within major lipid classes compared with placebo. We found a systematic increase in fatty acyls and a decrease in glycerolipids after CoQ10 treatment compared with placebo (<xref rid="F2" ref-type="fig">Figure 2</xref>). In comparison, NR supplementation was associated with a systemic decrease in glycerolipids and sphingolipids compared with placebo. NR also decreased plasma glycerophospholipids with the exception of 2 PC species (<xref rid="F2" ref-type="fig">Figure 2</xref> and <xref rid="sd" ref-type="sec">Supplemental Table 3</xref>).</p>
              </sec>
              <sec>
                <title>Oral supplementation with 1,000 mg/day of NR and 1,200 mg/day of CoQ10 was well tolerated and elicited no serious adverse effects.</title>
                <p>Twenty-three of the 25 participants consumed greater than 75% of NR, CoQ10, and placebo pills administered. We observed no difference in treatment-associated adverse events compared with placebo (<xref rid="sd" ref-type="sec">Supplemental Table 4</xref>). During the trial, a total of 13 adverse events were reported by the participants, with 6 during NR, 3 during CoQ10, and 4 during placebo supplementation. The adverse events were counted from the start of the treatment until the end of the washout period.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>In a randomized crossover trial testing 6 weeks of NR and CoQ10 treatments in patients with CKD, neither therapy improved the primary study outcomes of physical endurance measured by maximal aerobic capacity (VO<sub>2</sub> peak) and total work efficiency. Exploratory analysis, however, revealed that 6 weeks of NR improved submaximal exercise efficiency by reducing absolute VO<sub>2</sub> at 30 W and 60 W with a concomitant increase in RER, suggesting better efficiency in carbohydrate utilization at submaximal intensity. NR and CoQ10 treatments led to mechanistically plausible impacts on TCA cycle intermediates and lipid metabolites: CoQ10 increased plasma FFAs and decreased highly unsaturated medium- and long-chain triglycerides, and NR significantly altered plasma metabolites that are involved in reactions that use NAD<sup>+</sup> or NADP<sup>+</sup> as a cofactor, including 3 TCA cycle intermediates and glutamate. In addition to changes in plasma metabolites, NR supplementation resulted in a reduction in a wide range of lipid species, including triglycerides, ceramides, LPEs, LPCs, and PEs, compared with placebo. The treatments were generally well tolerated over the duration of the study. The observed impacts on the metabolic profile suggest early beneficial changes in systemic mitochondrial metabolism and lipid profile that argue for future trials with a longer treatment duration.</p>
              <p>Our findings are consistent with previous studies that also show no physical performance-enhancing effect from short-term CoQ10 or NR supplementation across a wide range of ages and physical fitness levels. A prior study of NR supplementation involving older males showed improved skeletal muscle NAD<sup>+</sup> levels and a reduction in circulating inflammatory cytokines after 21 days but no changes in grip strength or mitochondrial bioenergetics (<xref rid="B19" ref-type="bibr">19</xref>). Similarly, a 14-day CoQ10 supplementation among trained and untrained individuals showed reduction in plasma oxidative stress levels but no changes in anaerobic or aerobic capacity and ventilatory threshold (<xref rid="B20" ref-type="bibr">20</xref>). Negligible changes in metabolic substrate use indicated by comparable RER measurements at resting and 60 W after CoQ10 supplementation are also in agreement with previous findings. A randomized trial of patients with myalgia showed no changes in RER after 8 weeks of CoQ10 supplementation (<xref rid="B21" ref-type="bibr">21</xref>).</p>
              <p>Contrary to previous studies, we detected changes in VO<sub>2</sub> and RER at submaximal workloads (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>) in our post hoc exploratory analyses. In particular, we detected increased RER at 30 W and 60 W, suggesting enhanced carbohydrate utilization after NR supplementation. Higher submaximal RERs coincided with lower absolute VO<sub>2</sub> at submaximal workload, suggesting improved submaximal exercise efficiency. It is known that the NAD<sup>+</sup>/NADH ratio regulates oxidative metabolism through sirtuins (<xref rid="B24" ref-type="bibr">24</xref>). A possible explanation for the enhanced carbohydrate utilization with NR supplementation is improved SIRT1 activity that directly regulates mitochondrial function and biogenesis through PGC-1α (<xref rid="B25" ref-type="bibr">25</xref>). Studies have shown that NAD<sup>+</sup> supplementation modulates SIRT1 activity (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>), leading to improved glucose utilization via improved oxidative metabolism. A long-term (5 months) NR supplementation study among BMI-discordant twins showed increased muscle mitochondrial biogenesis linked to upregulation of <italic toggle="yes">SIRT1</italic>, <italic toggle="yes">TFAM</italic>, <italic toggle="yes">MFN2</italic>, and <italic toggle="yes">NRF1</italic> — all genes involved in glucose metabolism (<xref rid="B27" ref-type="bibr">27</xref>). The changes in multiple TCA cycle intermediates may support improved efficiency of energy metabolism underlying the increased submaximal RER with NR supplementation. This suggests that short-term NR supplementation may lead to improved energy expenditure from carbohydrates without impacting fat oxidation during light- to moderate-intensity exercise in CKD; however, further studies confirming this observation are needed. Together, our data along with published studies show that solely targeting mitochondrial dysfunction with short-term pharmacologic interventions does not counteract CKD-associated exercise intolerance. The complementary effects of CoQ10 and NR on lipid metabolism motivates future studies testing the combination of these supplements added to a structured exercise program to improve exercise tolerance in patients with CKD.</p>
              <p>CoQ10 supplementation in our study was associated with metabolic changes suggesting improved mitochondrial β oxidation known to be disrupted in CKD. CKD is associated with adverse metabolic complications, including dyslipidemia (<xref rid="B28" ref-type="bibr">28</xref>), amino acid and protein catabolism (<xref rid="B29" ref-type="bibr">29</xref>), and insulin resistance (<xref rid="B30" ref-type="bibr">30</xref>), contributing to impaired mitochondrial energy metabolism (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Prior studies have demonstrated CoQ10 supplementation reduces lipid peroxidation, a maker of oxidative stress, in patients with kidney failure (<xref rid="B32" ref-type="bibr">32</xref>). Impaired mitochondrial β oxidation and consequent lipid accumulation contributes to inflammation, oxidative stress, and insulin resistance in CKD (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Several lines of evidence suggest CoQ10 favorably impacts β oxidation. First, we observed biologically relevant alterations in the structure and amount of plasma FFAs and triglycerides after CoQ10 supplementation (<xref rid="sd" ref-type="sec">Supplemental Table 2</xref> and <xref rid="F2" ref-type="fig">Figure 2</xref>). Resting-state plasma FFA concentration is directly linked to the peak fat oxidation rate (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Further studies are needed to assess whether these changes in resting FFA reflect changes in insulin sensitivity. Second, CoQ10 supplementation resulted in a systemic decrease of medium- and long-chain triglycerides that accumulate in CKD and are hallmarks of impaired β oxidation (<xref rid="B36" ref-type="bibr">36</xref>). This also confirms previous studies showing reduction of serum triglycerides in response to CoQ10 supplementation (<xref rid="B37" ref-type="bibr">37</xref>). The reductions in longer triglycerides with high numbers of double bonds with CoQ10 treatment in our study suggests improved β oxidation. Finally, while not statistically significant (<italic toggle="yes">P</italic> = 0.07), there was a meaningful 41% increase in the plasma level of an important ketone body elevated in fatty acid oxidation, 3-hydroxybutyrate levels, a marker for β oxidation rate (<xref rid="B38" ref-type="bibr">38</xref>), with CoQ10. Our findings are consistent with prior in vitro and in vivo studies in mice showing improved β oxidation after CoQ10 supplementation (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Our results build on findings from previous studies confirming that CoQ10 supplementation improves the lipid profile in CKD by increasing β oxidation and decreasing plasma medium- and long-chain triglycerides. These findings motivate future trials involving longer durations of CoQ10 supplementation investigating long-term improvements in fatty acid oxidation and reduction in medium- and long-chain triglycerides. These future studies have clinical implications for dyslipidemia management in CKD and alleviating its metabolic and physiological complications such as insulin resistance, impaired energy metabolism, and oxidative stress.</p>
              <p>We found evidence that NR supplementation changed plasma levels of our targeted TCA cycle intermediates, suggesting improved systemic mitochondrial metabolism. Sufficient NAD<sup>+</sup> levels are needed for a wide range of anabolic and catabolic pathways, including glycolysis, TCA cycle, oxidative phosphorylation, fatty acid oxidation, and pentose phosphate pathway (<xref rid="B41" ref-type="bibr">41</xref>). Diminished NAD<sup>+</sup> biosynthesis results in depleted NAD<sup>+</sup> levels in CKD, contributing to impairment in energy-producing metabolic pathways (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B42" ref-type="bibr">42</xref>). We found significant alterations in 3 targeted TCA cycle intermediates (isocitrate, α-ketoglutarate, and malate) that exclusively use NAD<sup>+</sup> as a cofactor. In addition, glutamate, which is an anapleurotic precursor of α-ketoglutarate that uses NADP<sup>+</sup> as a cofactor, was also significantly altered. Our results in patients with CKD agree with prior studies of NR supplementation in murine models of aging. A study using muscle stem cells from aged mice showed that NR supplementation increases the expression of genes associated with TCA cycle and oxidative phosphorylation in addition to increased oxidative respiration, mitochondrial membrane potential, and ATP production (<xref rid="B43" ref-type="bibr">43</xref>). Further evidence for an impact of NR on mitochondrial function comes from a recent study of 12-week NR supplementation in heart failure patients with reduced ejection fraction, showing an increased mitochondrial respiration and decreased proinflammatory cytokine expression in PBMCs (<xref rid="B44" ref-type="bibr">44</xref>). Future studies are needed to assess mitochondrial metabolism impairments associated with reduced NAD<sup>+</sup> and the impact of NAD<sup>+</sup> precursor supplementation on ex vivo mitochondrial bioenergetics and oxidative phosphorylation capacity in CKD.</p>
              <p>NR treatment led to changes in the lipidomic profile, decreasing a broad range of plasma lipid species including triglycerides. CKD is known to be associated with disordered lipid metabolism with lower kidney function and greater albuminuria associated with impairments in β oxidation and higher levels of ceramides, triglycerides, and phosphatidylcholines (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). These lipid class alterations have been associated with biologic pathways of oxidative stress, insulin resistance, and inflammation in patients with CKD (<xref rid="B47" ref-type="bibr">47</xref>–<xref rid="B49" ref-type="bibr">49</xref>). NAD<sup>+</sup> is a crucial cofactor needed for β oxidation of fatty acids. NAD<sup>+</sup> deficiency in CKD contributes to impaired fatty acid β oxidation resulting in intracellular accumulation of lipids, including enrichment of triglycerides high in polyunsaturated fatty acids, which are thought to upregulate de novo biosynthesis of triglycerides and phospholipids via increased mitochondrial glycerol-3-phosphate acyltransferase (mtGPAT) signaling (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Although total triglyceride levels remained unchanged with NR supplementation, there was evidence of metabolically favorable changes, particularly in reductions in subclasses of triglycerides that were predominantly short and medium chained with a high degree of saturation. Consistent with another prior study of NAD<sup>+</sup> precursors in humans (<xref rid="B44" ref-type="bibr">44</xref>), our findings suggest that NR supplementation improved lipid metabolism by enhancing catabolism of shorter more saturated triglycerides without a significant impact on longer polyunsaturated triglycerides. However, future studies are needed to better understand the underlying mechanism of NAD<sup>+</sup> supplementation on improved triglyceride metabolism.</p>
              <p>In addition to reductions in triglycerides, NR treatment led to reductions in biologically relevant ceramides (a sphingolipid), LPEs, LPCs, and PEs (glycerophospholipids). The presence and severity of kidney disease is associated with increased ceramide levels known to adversely impact metabolic health (<xref rid="B52" ref-type="bibr">52</xref>). A recent large prospective cohort study showed that PEs, triglycerides, and ceramides are strongly associated with increased risk of CKD (<xref rid="B53" ref-type="bibr">53</xref>). Ceramides are considered lipotoxic, promoting lipid accumulation, insulin resistance, mitochondrial dysfunction, impaired β oxidation, inflammation, and apoptosis (<xref rid="B54" ref-type="bibr">54</xref>–<xref rid="B56" ref-type="bibr">56</xref>). Similarly, elevated LPE, LPC, and PE levels have also been implicated in cardiovascular disease, diabetes, and neurodegenerative disease (<xref rid="B57" ref-type="bibr">57</xref>–<xref rid="B59" ref-type="bibr">59</xref>). In our study, NR supplementation improved the plasma lipid profile by reducing lipotoxic species in CKD. Future studies are needed to investigate the underlying mechanism of improved CKD-associated dyslipidemia with increased NAD<sup>+</sup> bioavailability and its long-term effect on kidney function and other clinical outcomes. Key candidates for improved mitochondrial and lipid metabolism are NAD<sup>+</sup>-dependent mitochondrial sirtuins (and their downstream effectors) involved in mitochondrial biogenesis, mitochondrial dynamics, fatty acid oxidation, and oxidative stress defense (<xref rid="B60" ref-type="bibr">60</xref>).</p>
              <p>This study had notable strengths and limitations. First, we used an efficient and rigorous double dummy, placebo-controlled, randomized crossover trial design and physiologically relevant measures of endurance exercise capacity and substrate utilization during graded cycle ergometry testing. Second, we applied semitargeted metabolomics and lipidomics profiling and accounted for fasting status changes to identify changes in mitochondrial and lipid metabolism after NR and CoQ10 supplementation. However, this study had several limitations. First, the sample size was small and treatment duration was short, limiting evaluation to early potential treatment effects. This may have limited our ability to detect differences in muscle and exercise tolerance requiring longer-term treatment. Second, our study partially coincided with the start of the COVID-19 pandemic, leading to inevitable lifestyle changes among participants during the study period. We were unable to reliably track the impact this may have had on habitual physical activity. Third, a number of study participants were, on average, more active than the general CKD population who are, on average, much more sedentary (<xref rid="B61" ref-type="bibr">61</xref>). Fourth, we did not account for multiple comparisons in our lipidomics analyses. Nevertheless, our exploratory lipidomics analysis detected meaningful effects of CoQ10 and NR supplementation on specific biologically relevant functional classes of lipids known to be associated with CKD and demonstrated to have adverse effects on the kidney function. Finally, we did not have intracellular or tissue-specific (i.e., skeletal muscle) readouts of NAD<sup>+</sup> or CoQ10 before and after NR or CoQ10 supplementation to confirm higher intracellular levels of NAD<sup>+</sup> or CoQ10. Nonetheless, we did confirm a significant increase in plasma CoQ10 levels through our lipidomics analysis with an effect size of 1.3 (95% CI of 0.92 to 1.72) (<italic toggle="yes">P</italic> = 1.44 × 10<sup>–11</sup>) compared with placebo. Plasma and skeletal muscle CoQ10 levels have been shown to have a significant correlation in previous studies (<xref rid="B62" ref-type="bibr">62</xref>). Similarly, an NR supplementation study among older adults (70–80 years old) showed that 1,000 mg daily supplementation of NR for 21 days significantly elevated NAD<sup>+</sup> metabolome in the skeletal muscle (<xref rid="B19" ref-type="bibr">19</xref>).</p>
              <p>In contrast to the benefits of exercise in patients with CKD, our findings demonstrate NR or CoQ10 supplementation alone does not lead to improved maximal physical performance. Clinical trials of exercise training in persons with nondialysis CKD have shown significant improvements in maximal aerobic capacity, physical performance, and physical functioning (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>). Future studies combining exercise with these treatments are needed to detect synergy in improvement of metabolic health and exercise tolerance in patients with CKD given the overlapping mechanisms of exercise and NAD<sup>+</sup> precursor supplementation. Animal studies demonstrate NAD<sup>+</sup>-mediated mitochondrial hormetic response (mitohormesis), a well-known mediator of exercise-induced adaptations (<xref rid="B65" ref-type="bibr">65</xref>), through activation of SIRT1 and SIRT3 modulating mitochondrial fitness following NAD<sup>+</sup> precursor supplementation (<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>). In addition, a prior clinical trial in elderly adults combining 4 months of an antioxidant shown to induce SIRT1 and mitochondrial biogenesis (<xref rid="B68" ref-type="bibr">68</xref>) with exercise training demonstrated increases in muscle strength and physical endurance via 6-minute walking distance compared with exercise alone (<xref rid="B69" ref-type="bibr">69</xref>). Further human studies are needed to investigate the signaling systems involved in regulation of mitochondrial homeostasis via NAD<sup>+</sup> precursor supplementation and if they enhance mitohormetic effects improving adaptation to exercise training in CKD.</p>
              <p>In conclusion, short term CoQ10 and NR supplementation in patients with moderate to severe CKD resulted in biologically plausible changes in mitochondrial metabolism and the plasma lipid profile. Metabolic changes were more pronounced for the plasma lipidome than the metabolome. CoQ10 treatment led to improved β oxidation resulting in a systemic increase in plasma FFAs and a decrease in complex triglycerides while NR supplementation altered levels of TCA cycle intermediates and resulted in a broad decrease of plasma lipid species, including lipotoxic subclasses of sphingolipids. These findings add to the body of preclinical evidence supporting the efficacy of NR and CoQ10 for improving markers of mitochondrial metabolism and the lipid profile in persons with CKD not treated with dialysis. Given the distinct beneficial impacts of NR and CoQ10 on plasma metabolome and lipid profile, future studies of longer duration are needed to investigate the potential synergistic effects of a combination therapy of NR and CoQ10 in sedentary patients with CKD.</p>
            </sec>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec>
                <title>Study design and procedures</title>
                <p>CoQ10 and NR in CKD (CoNR trial) is a placebo-controlled, double-blind, randomized crossover trial with 3 arms: placebo, CoQ10, and NR (Clinicaltrials.gov NCT03579693). The trial was conducted from November 2018 to April 2021. There were 3 phases in the study, each 42 (6 weeks) days separated by a 1-week washout period. Subjects received 1,000 mg/day of NR (Niagen) or 1,200 mg/day of CoQ10 (Tishcon) for 6 weeks (<xref rid="sd" ref-type="sec">Supplemental Figure 1</xref>). The doses and study duration were chosen based on the review of studies in the literature evaluating biological activity, safety, and tolerability (<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>). A previous randomized, crossover trial of NR at 1,000 mg daily for 6 weeks demonstrated improvements in increasing NAD<sup>+</sup>-related metabolites coinciding with improvements in systolic BP (<xref rid="B70" ref-type="bibr">70</xref>). At all treatment periods, each participant took the same amount of identical-looking tablets. Participants, study physician, assessors, and study staff were blinded to the treatment and sequence allocation of participants.</p>
                <p>Adherence to the study treatment was assessed by phone call from the study coordinator midway through each treatment arm to confirm adherence and inventory method to assess remaining pills at the end of the study. Participants were asked to bring in unused study pills at each visit to return to The University of Washington Investigational Drug Services (IDS), which managed the study drugs. Adherence was defined as consumption of at least 75% of the prescribed regimen.</p>
                <p>There were 4 study visits in total for this trial: 1 baseline visit followed by 3 more at the end of each treatment period. The baseline visit was the same as visits 2, 3, and 4, with an addition of medical history and anthropometrics testing. Participants underwent baseline evaluation including a detailed assessment of demographics, smoking history, medical history, medication inventory, and vital signs. Independent functional status was obtained using an ADL score. These were collected using the Lawton-Bowdy Instrumental Activities of Daily Living (IADL) scale (<xref rid="B72" ref-type="bibr">72</xref>) coding responses as 0 and 1 summed to a total score of 8, with 8 being the most independent and 0 being the least independent. To avoid introducing any potential bias into the study, the participants were asked to avoid making any changes to their habitual physical activity during the trial. All concomitant medications taken by the participants within 4 weeks prior to study enrollment were recorded. In addition to the prescribed medication, over-the-counter medications (i.e., vitamins, herbal remedies) were also recorded. The participants were also asked to fast at least 6 hours before each visit and abstain from caffeine intake, smoking, and exercising 48 hours before bicycle ergometry testing. Alcohol and recreational or street drug use was also recorded for interpretation and documentation of observed participant health status. These were verified by the study coordinators the day of testing. During each visit, blood and cycle ergometry data were collected for each participant.</p>
                <p>A brief screening process to evaluate eligibility criteria and to obtain informed consent took place approximately 1 month before the baseline visit. The screening visit included verification of inclusion and exclusion criteria, measuring vital signs, anthropometrics, 6-minute walking distance, screening labs (renal panel and complete blood count), and bicycle ergometry practice to familiarize participants with the equipment. Qualified participants were randomized to a supplementation sequence (<xref rid="sd" ref-type="sec">Supplemental Figure 1</xref>).</p>
              </sec>
              <sec>
                <title>Study population</title>
                <p>Study participants were selected from a larger observational cohort study of muscle energetics in CKD: the Muscle Mitochondrial Energetics and Dysfunction (MEND) study (<xref rid="B6" ref-type="bibr">6</xref>). Additional participants were recruited from nephrology clinics at the University of Washington System, including Harborview Medical Center and University of Washington Medical Center. Inclusion criteria were ages 30–79, eGFR of less than 60mL/min/1.73 m<sup>2</sup> (using the creatinine-based 2012 Chronic Kidney Disease Epidemiology Collaboration equation), and a 6-minute walking distance of less than 550 meters. Exclusion criteria included insulin-dependent diabetes, treatment with dialysis, kidney transplantation, and weight of over 300 lb. A total of 25 participants were recruited for the study (<xref rid="T1" ref-type="table">Table 1</xref>). The last participant exited the study in April 2021.</p>
              </sec>
              <sec>
                <title>Physical endurance measurements</title>
                <p>The primary outcomes of the study were changes in physical exercise endurance measured by aerobic capacity (VO<sub>2</sub> peak), total work, and work efficiency. We also measured RER via cycle ergometry (Lode Corival Cycle Ergometer, MGC Diagnostics Ultima CardiO<sub>2</sub> pulmonary exercise system). These measurements were obtained in a dedicated exercise research center at the Fred Hutchinson Cancer Center using cycle ergometry measuring oxygen uptake starting at 0 W at 60 rotations per minute (rpm) and increasing it by 30 W every 3 minutes until exhaustion. If participants were to complete 120 W for 3 minutes, they would continue pedaling at 120 W until exhaustion. A mean rate of perceived exertion (RPE) of greater than 17 (Borg scale) and a mean RER of 1.109 ±.099 were achieved across all visits, suggesting maximal effort was given by the participants (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>). The VO<sub>2</sub> was measured as 30-second averages. The VO<sub>2</sub> peak was defined as the highest VO<sub>2</sub> obtained during the last 30 seconds of the exercise testing. Total work performed (kJ) was calculated as follows: (W × seconds)/1,000. Work efficiency during exercise testing was calculated as follows: total work/VO<sub>2</sub> peak. RER at rest, 30 W, 60 W, and max workload were measured as the last 30-second averaged RER of each specific stage (rest, 30 W, 60 W, and VO<sub>2</sub> max).</p>
              </sec>
              <sec>
                <title>Metabolic profiling</title>
                <p>We evaluated changes in plasma metabolites and circulating lipid species through semitargeted metabolomics and lipidomics profiling approaches using gas chromatography coupled to time-of-flight mass spectrometry (GC TOF-MS) and liquid chromatography coupled to quadrupole time-of-flight mass spectrometer-charged surface hybrid (LC QTOF CHS), respectively, as described before (<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B76" ref-type="bibr">76</xref>). A priori–selected metabolites that use NAD<sup>+</sup>/NADP<sup>+</sup> as cofactors were targeted for plasma metabolites based on their anticipated response to the study treatments. These metabolites include pyruvate, malate, lactate, isocitrate, glutamate, glucose-6-phosphate, and α-ketoglutarate. Both platforms were performed at West Coast Metabolomics Center. A total of 98 plasma metabolites and 394 lipid species were detected across all 4 visits.</p>
              </sec>
              <sec>
                <title>Statistics</title>
                <sec>
                  <title>Physical endurance.</title>
                  <p>We used ANOVA to estimate sequence effects, treatment effects, and period effects on physical performance outcomes. The coefficient of the interaction term between the treatment (NR, CoQ10, and placebo) and time point (before versus after) was used to estimate the treatment effect for each intervention. The impact of treatment on BW, kidney function biomarkers, and cystatin C was estimated using the method. To estimate treatment effect in the stratified analysis of physical endurance outcomes, the interaction term of activity level (active versus sedentary) and treatment or performance (poor versus good performers) and treatment were used. Treatment effects in the gender-stratified comparison were estimated using the interaction term of sex (male versus female) and treatment. We tested for possible carryover effects of the study interventions using the interaction of study period and treatment. One-way ANOVA and 2-way ANOVA were performed using GraphPad Prism 9.0. A <italic toggle="yes">P</italic> value of less than 0.05 was considered significant for all analyses unless stated otherwise.</p>
                </sec>
                <sec>
                  <title>Subgroup analysis.</title>
                  <p>Participants were grouped into the “active” category if they were physically active for at least 300 minutes (moderate intensity) per month, according to their self-reported online survey. This threshold was picked based on the recommendation of the Physical Activity Guidelines for Americans (2nd edition) for our participants’ age demographics with chronic conditions (<xref rid="B77" ref-type="bibr">77</xref>). The second grouping strategy was based on participants’ performance during their baseline cycle ergometry testing. The participants who completed 3 minutes at all stages of the exercise protocol from 0 W to 120 W were included, which equals a minimum of 15 minutes total test duration, and were labeled as “good performers.” The participants who were unable to complete the last stage of 120 W and therefore had a test duration less than 15 minutes were labeled “poor performers.”</p>
                </sec>
                <sec>
                  <title>Metabolomics and lipidomics.</title>
                  <p>Plasma metabolites were available for 25 participants for all 4 visits except for 1 participant who missed a post-CoQ10 visit. All metabolites were checked for normality. To eliminate systematic variation during sample preparation, raw metabolites were normalized using Systematic Error Removal Using Random Forest (SERRF) (<xref rid="B78" ref-type="bibr">78</xref>). Differences in plasma metabolites were assessed using a linear mixed modeling approach with random intercepts in which SERRF-normalized metabolites were regressed on treatment type (placebo versus CoQ10 or NR), time point (before versus after), and the interaction of the 2, additionally adjusted for fasting status. Fold changes were calculated using the mean ratio of postsupplementation (CoQ10 or NR) over placebo. To quantify the magnitude of impact on the plasma metabolic and lipid profile, we determined the effect size using standardized mean difference (<xref rid="B79" ref-type="bibr">79</xref>). An effect size of 0.5 is considered a medium effect and an effect size above 0.8 is considered a large effect. Linear mixed effects modeling was also used to perform carryover analysis to confirm negligible lingering effects from each supplementation period. Data are presented as mean ± SD unless otherwise stated. Statistical analysis was performed using R 3.6.1 (<xref rid="B80" ref-type="bibr">80</xref>).</p>
                </sec>
                <sec>
                  <title>Power calculations.</title>
                  <p>Sample size was calculated based on a pilot, randomized, controlled trial study of patients with CKD demonstrating the effect of a 12-month combined resistance and aerobic exercise program resulting in an increase of 5.7 mL/kg/min VO<sub>2</sub> peak with a standard deviation of the difference in VO<sub>2</sub> peak on bicycle ergometry of 2.1 mL/kg/min (<xref rid="B81" ref-type="bibr">81</xref>). The probability is 92% that the study will detect a treatment difference at a 2-sided 0.05 significance level, if the true difference between treatments is 2.1 (1 SD) mL/kg/min. This assumes that the standard deviation of the difference in the response variables is 2.1 mL/kg/min. The same power calculation was employed for each treatment.</p>
                </sec>
              </sec>
              <sec>
                <title>Study approval</title>
                <p>The procedures in the study and model informed consent forms were reviewed by the University of Washington Human Subjects Division (HSD). All participants provided written informed consent. The study was approved by the ethical review board of University of Washington (STUDY00004998).</p>
              </sec>
            </sec>
            <sec>
              <title>Author contributions</title>
              <p>The conceptualization was contributed by AA, BR, GB, DJM, and BRK. The methodology was contributed by AA, SF, DKP, DJM, BR, and BRK. The formal analysis was conducted by AA and SF. The investigation was performed by BR, BRK, and DKP. Resources were contributed by BRK, BR, JG, and DKP. Data curation was performed by AA, SF, and DKP. The original draft was written by AA and BR. The review was written and edited by AA, BR, GB, APV, JG, JEN, BJB, MPV, BL, DKP, BRK, IHDB, JH, DJM, and BRK. Visualization was contributed by AA and SF. Supervision was carried out by BR, BRK, and DKP. Project administration was contributed by BRK, DKP, IHDB, JH, and BR. Funding acquisition was contributed by BR and BRK.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sd">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <caption>
                  <title>Supplemental data</title>
                </caption>
                <media xlink:href="jciinsight-8-167274-s299.pdf" id="d64e1053" position="anchor"/>
              </supplementary-material>
              <supplementary-material id="SD2" position="float" content-type="local-data">
                <caption>
                  <title>ICMJE disclosure forms</title>
                </caption>
                <media xlink:href="jciinsight-8-167274-s300.pdf" id="d64e1057" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank all the study participants for being part of this trial. We also thank ChromaDex as the manufacturer and provider of Niagen for this study. This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK101509 (to BRK), grant R03 DK114502 (to BR), grant R01 DK125794 (to BR), and grant R01 DK101509 (to JG). Support was also provided by Dialysis Clinics grant C-4112 (to BR) and the Northern California VA Health Care System (to BR).</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement">
                <p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
              </fn>
              <fn>
                <p><bold>Copyright:</bold> © 2023, Ahmadi et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.</p>
              </fn>
              <fn>
                <p><bold>Reference information:</bold><italic toggle="yes"> JCI Insight</italic>. 2023;8(11):e167274.https://doi.org/10.1172/jci.insight.167274.</p>
              </fn>
            </fn-group>
            <ref-list>
              <ref id="B1">
                <label>1</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tsai</surname>
                      <given-names>YC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Association of physical activity with cardiovascular and renal outcomes and quality of life in chronic kidney disease</article-title>
                  <source>PLoS One</source>
                  <year>2017</year>
                  <volume>12</volume>
                  <issue>8</issue>
                  <elocation-id>e0183642</elocation-id>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0183642</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5568323</pub-id>-->
                  <?supplied-pmid 28832653?>
                  <pub-id pub-id-type="pmid">28832653</pub-id>
                </element-citation>
              </ref>
              <ref id="B2">
                <label>2</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roshanravan</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Exercise and CKD: skeletal muscle dysfunction and practical application of exercise to prevent and treat physical impairments in CKD</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2017</year>
                  <volume>69</volume>
                  <issue>6</issue>
                  <fpage>837</fpage>
                  <lpage>852</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.ajkd.2017.01.051</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5441955</pub-id>-->
                  <?supplied-pmid 28427790?>
                  <pub-id pub-id-type="pmid">28427790</pub-id>
                </element-citation>
              </ref>
              <ref id="B3">
                <label>3</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirkman</surname>
                      <given-names>DL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Exercise intolerance in kidney diseases: physiological contributors and therapeutic strategies</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2021</year>
                  <volume>320</volume>
                  <issue>2</issue>
                  <fpage>F161</fpage>
                  <lpage>F173</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00437.2020</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7948123</pub-id>-->
                  <?supplied-pmid 33283641?>
                  <pub-id pub-id-type="pmid">33283641</pub-id>
                </element-citation>
              </ref>
              <ref id="B4">
                <label>4</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Relationship between chronic kidney disease and sarcopenia</article-title>
                  <source>Sci Rep</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <issue>1</issue>
                  <elocation-id>20523</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41598-021-99592-3</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8520007</pub-id>-->
                  <?supplied-pmid 34654871?>
                  <pub-id pub-id-type="pmid">34654871</pub-id>
                </element-citation>
              </ref>
              <ref id="B5">
                <label>5</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sabatino</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Sarcopenia in chronic kidney disease: what have we learned so far?</article-title>
                  <source>J Nephrol</source>
                  <year>2021</year>
                  <volume>34</volume>
                  <issue>4</issue>
                  <fpage>1347</fpage>
                  <lpage>1372</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40620-020-00840-y</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8357704</pub-id>-->
                  <?supplied-pmid 32876940?>
                  <pub-id pub-id-type="pmid">32876940</pub-id>
                </element-citation>
              </ref>
              <ref id="B6">
                <label>6</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kestenbaum</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease</article-title>
                  <source>JCI Insight</source>
                  <year>2020</year>
                  <volume>5</volume>
                  <issue>5</issue>
                  <elocation-id>e133289</elocation-id>
                  <pub-id pub-id-type="doi">10.1172/jci.insight.133289</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7141399</pub-id>-->
                  <?supplied-pmid 32161192?>
                  <pub-id pub-id-type="pmid">32161192</pub-id>
                </element-citation>
              </ref>
              <ref id="B7">
                <label>7</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>López-Lluch</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Is coenzyme Q a key factor in aging?</article-title>
                  <source>Mech Ageing Dev</source>
                  <year>2010</year>
                  <volume>131</volume>
                  <issue>4</issue>
                  <fpage>225</fpage>
                  <lpage>235</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.mad.2010.02.003</pub-id>
                  <?supplied-pmid 20193705?>
                  <pub-id pub-id-type="pmid">20193705</pub-id>
                </element-citation>
              </ref>
              <ref id="B8">
                <label>8</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hernández-Camacho</surname>
                      <given-names>JD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coenzyme Q10 supplementation in aging and disease. Review</article-title>
                  <source>Front Physiol</source>
                  <year>2018</year>
                  <volume>9</volume>
                  <elocation-id>44</elocation-id>
                  <pub-id pub-id-type="doi">10.3389/fphys.2018.00044</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5807419</pub-id>-->
                  <?supplied-pmid 29459830?>
                  <pub-id pub-id-type="pmid">29459830</pub-id>
                </element-citation>
              </ref>
              <ref id="B9">
                <label>9</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yeung</surname>
                      <given-names>CK</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress</article-title>
                  <source>BMC Nephrol</source>
                  <year>2015</year>
                  <volume>16</volume>
                  <issue>1</issue>
                  <elocation-id>183</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/s12882-015-0178-2</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4630830</pub-id>-->
                  <?supplied-pmid 26531095?>
                  <pub-id pub-id-type="pmid">26531095</pub-id>
                </element-citation>
              </ref>
              <ref id="B10">
                <label>10</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tian</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Ubiquinol-10 supplementation activates mitochondria functions to decelerate senescence in senescence-accelerated mice</article-title>
                  <source>Antioxid Redox Signal</source>
                  <year>2014</year>
                  <volume>20</volume>
                  <issue>16</issue>
                  <fpage>2606</fpage>
                  <lpage>2620</lpage>
                  <pub-id pub-id-type="doi">10.1089/ars.2013.5406</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4025630</pub-id>-->
                  <?supplied-pmid 24124769?>
                  <pub-id pub-id-type="pmid">24124769</pub-id>
                </element-citation>
              </ref>
              <ref id="B11">
                <label>11</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition</article-title>
                  <source>Sci Rep</source>
                  <year>2017</year>
                  <volume>7</volume>
                  <issue>1</issue>
                  <elocation-id>8253</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41598-017-08899-7</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5557856</pub-id>-->
                  <?supplied-pmid 28811612?>
                  <pub-id pub-id-type="pmid">28811612</pub-id>
                </element-citation>
              </ref>
              <ref id="B12">
                <label>12</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Amjad</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Role of NAD<sup>+</sup> in regulating cellular and metabolic signaling pathways</article-title>
                  <source>Mol Metab</source>
                  <year>2021</year>
                  <volume>49</volume>
                  <elocation-id>101195</elocation-id>
                  <pub-id pub-id-type="doi">10.1016/j.molmet.2021.101195</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7973386</pub-id>-->
                  <?supplied-pmid 33609766?>
                  <pub-id pub-id-type="pmid">33609766</pub-id>
                </element-citation>
              </ref>
              <ref id="B13">
                <label>13</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impaired nicotinamide adenine dinucleotide biosynthesis in the kidney of chronic kidney disease</article-title>
                  <source>Front Physiol</source>
                  <year>2021</year>
                  <volume>12</volume>
                  <elocation-id>723690</elocation-id>
                  <pub-id pub-id-type="doi">10.3389/fphys.2021.723690</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8484911</pub-id>-->
                  <?supplied-pmid 34603081?>
                  <pub-id pub-id-type="pmid">34603081</pub-id>
                </element-citation>
              </ref>
              <ref id="B14">
                <label>14</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Slee</surname>
                      <given-names>AD</given-names>
                    </name>
                  </person-group>
                  <article-title>Exploring metabolic dysfunction in chronic kidney disease</article-title>
                  <source>Nutr Metab (Lond)</source>
                  <year>2012</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <elocation-id>36</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/1743-7075-9-36</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3407016</pub-id>-->
                  <?supplied-pmid 22537670?>
                  <pub-id pub-id-type="pmid">22537670</pub-id>
                </element-citation>
              </ref>
              <ref id="B15">
                <label>15</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ralto</surname>
                      <given-names>KM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD<sup>+</sup> homeostasis in renal health and disease</article-title>
                  <source>Nat Rev Nephrol</source>
                  <year>2020</year>
                  <volume>16</volume>
                  <issue>2</issue>
                  <fpage>99</fpage>
                  <lpage>111</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41581-019-0216-6</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7223841</pub-id>-->
                  <?supplied-pmid 31673160?>
                  <pub-id pub-id-type="pmid">31673160</pub-id>
                </element-citation>
              </ref>
              <ref id="B16">
                <label>16</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cantó</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity</article-title>
                  <source>Cell Metab</source>
                  <year>2012</year>
                  <volume>15</volume>
                  <issue>6</issue>
                  <fpage>838</fpage>
                  <lpage>847</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2012.04.022</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3616313</pub-id>-->
                  <?supplied-pmid 22682224?>
                  <pub-id pub-id-type="pmid">22682224</pub-id>
                </element-citation>
              </ref>
              <ref id="B17">
                <label>17</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stromsdorfer</surname>
                      <given-names>Kelly L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAMPT-mediated NAD<sup>+</sup> biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice</article-title>
                  <source>Cell Reports</source>
                  <year>2016</year>
                  <volume>16</volume>
                  <issue>7</issue>
                  <fpage>1851</fpage>
                  <lpage>1860</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.027</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5094180</pub-id>-->
                  <?supplied-pmid 27498863?>
                  <pub-id pub-id-type="pmid">27498863</pub-id>
                </element-citation>
              </ref>
              <ref id="B18">
                <label>18</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gomboa</surname>
                      <given-names>JL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Is present in patients with CKD before initiation of maintenance hemodialysis</article-title>
                  <source>Clin J Am Soc Nephrol</source>
                  <year>2020</year>
                  <volume>15</volume>
                  <issue>7</issue>
                  <fpage>926</fpage>
                  <lpage>936</lpage>
                  <pub-id pub-id-type="doi">10.2215/CJN.10320819</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7341789</pub-id>-->
                  <?supplied-pmid 32591419?>
                  <pub-id pub-id-type="pmid">32591419</pub-id>
                </element-citation>
              </ref>
              <ref id="B19">
                <label>19</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Elhassan</surname>
                      <given-names>YS</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Nicotinamide riboside augments the aged human skeletal muscle NAD<sup>+</sup> metabolome and induces transcriptomic and anti-inflammatory signatures</article-title>
                  <source>Cell Rep</source>
                  <year>2019</year>
                  <volume>28</volume>
                  <issue>7</issue>
                  <fpage>1717</fpage>
                  <lpage>1728</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.043</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6702140</pub-id>-->
                  <?supplied-pmid 31412242?>
                  <pub-id pub-id-type="pmid">31412242</pub-id>
                </element-citation>
              </ref>
              <ref id="B20">
                <label>20</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooke</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals</article-title>
                  <source>J Int Soc Sports Nutr</source>
                  <year>2008</year>
                  <volume>5</volume>
                  <elocation-id>8</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/1550-2783-5-8</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2315638</pub-id>-->
                  <?supplied-pmid 18318910?>
                  <pub-id pub-id-type="pmid">18318910</pub-id>
                </element-citation>
              </ref>
              <ref id="B21">
                <label>21</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Taylor</surname>
                      <given-names>BA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy</article-title>
                  <source>Atherosclerosis</source>
                  <year>2015</year>
                  <volume>238</volume>
                  <issue>2</issue>
                  <fpage>329</fpage>
                  <lpage>335</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.12.016</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4298455</pub-id>-->
                  <?supplied-pmid 25545331?>
                  <pub-id pub-id-type="pmid">25545331</pub-id>
                </element-citation>
              </ref>
              <ref id="B22">
                <label>22</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Connell</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD+-precursor supplementation with L-tryptophan, nicotinic acid, and nicotinamide does not affect mitochondrial function or skeletal muscle function in physically compromised older adults</article-title>
                  <source>J Nutr</source>
                  <year>2021</year>
                  <volume>151</volume>
                  <issue>10</issue>
                  <fpage>2917</fpage>
                  <lpage>2931</lpage>
                  <pub-id pub-id-type="doi">10.1093/jn/nxab193</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8485915</pub-id>-->
                  <?supplied-pmid 34191033?>
                  <pub-id pub-id-type="pmid">34191033</pub-id>
                </element-citation>
              </ref>
              <ref id="B23">
                <label>23</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stocks</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Nicotinamide riboside supplementation does not alter whole-body or skeletal muscle metabolic responses to a single bout of endurance exercise</article-title>
                  <source>J Physiol</source>
                  <year>2021</year>
                  <volume>599</volume>
                  <issue>5</issue>
                  <fpage>1513</fpage>
                  <lpage>1531</lpage>
                  <pub-id pub-id-type="doi">10.1113/JP280825</pub-id>
                  <?supplied-pmid 33492681?>
                  <pub-id pub-id-type="pmid">33492681</pub-id>
                </element-citation>
              </ref>
              <ref id="B24">
                <label>24</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sauve</surname>
                      <given-names>AA</given-names>
                    </name>
                  </person-group>
                  <article-title>NAD(+) metabolism: bioenergetics, signaling and manipulation for therapy</article-title>
                  <source>Biochim Biophys Acta</source>
                  <year>2016</year>
                  <volume>1864</volume>
                  <issue>12</issue>
                  <fpage>1787</fpage>
                  <lpage>1800</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.bbapap.2016.06.014</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5521000</pub-id>-->
                  <?supplied-pmid 27374990?>
                  <pub-id pub-id-type="pmid">27374990</pub-id>
                </element-citation>
              </ref>
              <ref id="B25">
                <label>25</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Houtkooper</surname>
                      <given-names>RH</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways</article-title>
                  <source>Endocr Rev</source>
                  <year>2010</year>
                  <volume>31</volume>
                  <issue>2</issue>
                  <fpage>194</fpage>
                  <lpage>223</lpage>
                  <pub-id pub-id-type="doi">10.1210/er.2009-0026</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2852209</pub-id>-->
                  <?supplied-pmid 20007326?>
                  <pub-id pub-id-type="pmid">20007326</pub-id>
                </element-citation>
              </ref>
              <ref id="B26">
                <label>26</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yoshino</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice</article-title>
                  <source>Cell Metab</source>
                  <year>2011</year>
                  <volume>14</volume>
                  <issue>4</issue>
                  <fpage>528</fpage>
                  <lpage>536</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.014</pub-id>
                  <!--<pub-id pub-id-type="pmcid">3204926</pub-id>-->
                  <?supplied-pmid 21982712?>
                  <pub-id pub-id-type="pmid">21982712</pub-id>
                </element-citation>
              </ref>
              <ref id="B27">
                <label>27</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lapatto</surname>
                      <given-names>HAK</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study</article-title>
                  <source>Sci Adv</source>
                  <year>2023</year>
                  <volume>9</volume>
                  <issue>2</issue>
                  <elocation-id>eadd5163</elocation-id>
                  <pub-id pub-id-type="doi">10.1126/sciadv.add5163</pub-id>
                  <!--<pub-id pub-id-type="pmcid">9839336</pub-id>-->
                  <?supplied-pmid 36638183?>
                  <pub-id pub-id-type="pmid">36638183</pub-id>
                </element-citation>
              </ref>
              <ref id="B28">
                <label>28</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mikolasevic</surname>
                      <given-names>I</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Dyslipidemia in patients with chronic kidney disease: etiology and management</article-title>
                  <source>Int J Nephrol Renovasc Dis</source>
                  <year>2017</year>
                  <volume>10</volume>
                  <fpage>35</fpage>
                  <lpage>45</lpage>
                  <pub-id pub-id-type="doi">10.2147/IJNRD.S101808</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5304971</pub-id>-->
                  <?supplied-pmid 28223836?>
                  <pub-id pub-id-type="pmid">28223836</pub-id>
                </element-citation>
              </ref>
              <ref id="B29">
                <label>29</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Garibotto</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease</article-title>
                  <source>Clin Nutr</source>
                  <year>2010</year>
                  <volume>29</volume>
                  <issue>4</issue>
                  <fpage>424</fpage>
                  <lpage>433</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.clnu.2010.02.005</pub-id>
                  <?supplied-pmid 20207454?>
                  <pub-id pub-id-type="pmid">20207454</pub-id>
                </element-citation>
              </ref>
              <ref id="B30">
                <label>30</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spoto</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Insulin resistance in chronic kidney disease: a systematic review</article-title>
                  <source>Am J Physiol Renal Physiol</source>
                  <year>2016</year>
                  <volume>311</volume>
                  <issue>6</issue>
                  <fpage>F1087</fpage>
                  <lpage>F1108</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajprenal.00340.2016</pub-id>
                  <?supplied-pmid 27707707?>
                  <pub-id pub-id-type="pmid">27707707</pub-id>
                </element-citation>
              </ref>
              <ref id="B31">
                <label>31</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Conjard</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effects of chronic renal failure on enzymes of energy metabolism in individual human muscle fibers</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>1995</year>
                  <volume>6</volume>
                  <issue>1</issue>
                  <fpage>68</fpage>
                  <lpage>74</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.V6168</pub-id>
                  <?supplied-pmid 7579072?>
                  <pub-id pub-id-type="pmid">7579072</pub-id>
                </element-citation>
              </ref>
              <ref id="B32">
                <label>32</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rivara</surname>
                      <given-names>MB</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of coenzyme Q(10) on biomarkers of oxidative stress and cardiac function in hemodialysis patients: the CoQ(10) biomarker trial</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2017</year>
                  <volume>69</volume>
                  <issue>3</issue>
                  <fpage>389</fpage>
                  <lpage>399</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.ajkd.2016.08.041</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5616172</pub-id>-->
                  <?supplied-pmid 27927588?>
                  <pub-id pub-id-type="pmid">27927588</pub-id>
                </element-citation>
              </ref>
              <ref id="B33">
                <label>33</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jang</surname>
                      <given-names>HS</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Defective mitochondrial fatty acid oxidation and lipotoxicity in kidney diseases</article-title>
                  <source>Front Med (lausanne)</source>
                  <year>2020</year>
                  <volume>7</volume>
                  <elocation-id>65</elocation-id>
                  <!--<pub-id pub-id-type="pmcid">7080698</pub-id>-->
                  <?supplied-pmid 32226789?>
                  <pub-id pub-id-type="pmid">32226789</pub-id>
                </element-citation>
              </ref>
              <ref id="B34">
                <label>34</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bonadonna</surname>
                      <given-names>RC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans</article-title>
                  <source>Am J Physiol</source>
                  <year>1990</year>
                  <volume>259</volume>
                  <issue>5</issue>
                  <fpage>E736</fpage>
                  <lpage>E750</lpage>
                  <?supplied-pmid 2240211?>
                  <pub-id pub-id-type="pmid">2240211</pub-id>
                </element-citation>
              </ref>
              <ref id="B35">
                <label>35</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frandsen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Plasma free fatty acid concentration is closely tied to whole body peak fat oxidation rate during repeated exercise</article-title>
                  <source>J Appl Physiol (1985)</source>
                  <year>2019</year>
                  <volume>126</volume>
                  <issue>6</issue>
                  <fpage>1563</fpage>
                  <lpage>1571</lpage>
                  <pub-id pub-id-type="doi">10.1152/japplphysiol.00995.2018</pub-id>
                  <?supplied-pmid 30844337?>
                  <pub-id pub-id-type="pmid">30844337</pub-id>
                </element-citation>
              </ref>
              <ref id="B36">
                <label>36</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Afshinnia</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impaired β-oxidation and altered complex lipid fatty acid partitioning with advancing CKD</article-title>
                  <source>J Am Soc Nephrol</source>
                  <year>2018</year>
                  <volume>29</volume>
                  <issue>1</issue>
                  <fpage>295</fpage>
                  <lpage>306</lpage>
                  <pub-id pub-id-type="doi">10.1681/ASN.2017030350</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5748913</pub-id>-->
                  <?supplied-pmid 29021384?>
                  <pub-id pub-id-type="pmid">29021384</pub-id>
                </element-citation>
              </ref>
              <ref id="B37">
                <label>37</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals</article-title>
                  <source>J Clin Lipidol</source>
                  <year>2018</year>
                  <volume>12</volume>
                  <issue>2</issue>
                  <fpage>417</fpage>
                  <lpage>427</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacl.2017.12.006</pub-id>
                  <?supplied-pmid 29454678?>
                  <pub-id pub-id-type="pmid">29454678</pub-id>
                </element-citation>
              </ref>
              <ref id="B38">
                <label>38</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mierziak</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>3-hydroxybutyrate as a metabolite and a signal molecule regulating processes of living organisms</article-title>
                  <source>Biomolecules</source>
                  <year>2021</year>
                  <volume>11</volume>
                  <issue>3</issue>
                  <elocation-id>402</elocation-id>
                  <pub-id pub-id-type="doi">10.3390/biom11030402</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8000602</pub-id>-->
                  <?supplied-pmid 33803253?>
                  <pub-id pub-id-type="pmid">33803253</pub-id>
                </element-citation>
              </ref>
              <ref id="B39">
                <label>39</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chokchaiwong</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coenzyme Q10 serves to couple mitochondrial oxidative phosphorylation and fatty acid β-oxidation, and attenuates NLRP3 inflammasome activation</article-title>
                  <source>Free Radic Res</source>
                  <year>2018</year>
                  <volume>52</volume>
                  <issue>11–12</issue>
                  <fpage>1445</fpage>
                  <lpage>1455</lpage>
                  <?supplied-pmid 30003820?>
                  <pub-id pub-id-type="pmid">30003820</pub-id>
                </element-citation>
              </ref>
              <ref id="B40">
                <label>40</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carmona</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice</article-title>
                  <source>Int J Obes (Lond)</source>
                  <year>2009</year>
                  <volume>33</volume>
                  <issue>2</issue>
                  <fpage>204</fpage>
                  <lpage>211</lpage>
                  <pub-id pub-id-type="doi">10.1038/ijo.2008.265</pub-id>
                  <?supplied-pmid 19125161?>
                  <pub-id pub-id-type="pmid">19125161</pub-id>
                </element-citation>
              </ref>
              <ref id="B41">
                <label>41</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xie</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD<sup>+</sup> metabolism: pathophysiologic mechanisms and therapeutic potential</article-title>
                  <source>Signal Transduct Target Ther</source>
                  <year>2020</year>
                  <volume>5</volume>
                  <issue>1</issue>
                  <elocation-id>227</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41392-020-00311-7</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7539288</pub-id>-->
                  <?supplied-pmid 33028824?>
                  <pub-id pub-id-type="pmid">33028824</pub-id>
                </element-citation>
              </ref>
              <ref id="B42">
                <label>42</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ying</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD+ as a metabolic link between DNA damage and cell death</article-title>
                  <source>J Neurosci Res</source>
                  <year>2005</year>
                  <volume>79</volume>
                  <issue>1-2</issue>
                  <fpage>216</fpage>
                  <lpage>223</lpage>
                  <pub-id pub-id-type="doi">10.1002/jnr.20289</pub-id>
                  <?supplied-pmid 15562437?>
                  <pub-id pub-id-type="pmid">15562437</pub-id>
                </element-citation>
              </ref>
              <ref id="B43">
                <label>43</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice</article-title>
                  <source>Science</source>
                  <year>2016</year>
                  <volume>352</volume>
                  <issue>6292</issue>
                  <fpage>1436</fpage>
                  <lpage>1443</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.aaf2693</pub-id>
                  <?supplied-pmid 27127236?>
                  <pub-id pub-id-type="pmid">27127236</pub-id>
                </element-citation>
              </ref>
              <ref id="B44">
                <label>44</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>DD</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction</article-title>
                  <source>JACC: Basic Transl Sci</source>
                  <year>2022</year>
                  <volume>7</volume>
                  <issue>12</issue>
                  <fpage>1183</fpage>
                  <lpage>1196</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jacbts.2022.06.012</pub-id>
                  <!--<pub-id pub-id-type="pmcid">9831861</pub-id>-->
                  <?supplied-pmid 36644285?>
                  <pub-id pub-id-type="pmid">36644285</pub-id>
                </element-citation>
              </ref>
              <ref id="B45">
                <label>45</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Choudhury</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Disorders of lipid metabolism and chronic kidney disease in the elderly</article-title>
                  <source>Semin Nephrol</source>
                  <year>2009</year>
                  <volume>29</volume>
                  <issue>6</issue>
                  <fpage>610</fpage>
                  <lpage>620</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.semnephrol.2009.07.006</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2806221</pub-id>-->
                  <?supplied-pmid 20006793?>
                  <pub-id pub-id-type="pmid">20006793</pub-id>
                </element-citation>
              </ref>
              <ref id="B46">
                <label>46</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tofte</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes</article-title>
                  <source>Sci Rep</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <elocation-id>16398</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41598-019-52916-w</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6841673</pub-id>-->
                  <?supplied-pmid 31705008?>
                  <pub-id pub-id-type="pmid">31705008</pub-id>
                </element-citation>
              </ref>
              <ref id="B47">
                <label>47</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bulbul</surname>
                      <given-names>MC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Disorders of lipid metabolism in chronic kidney disease</article-title>
                  <source>Blood Purif</source>
                  <year>2018</year>
                  <volume>46</volume>
                  <issue>2</issue>
                  <fpage>144</fpage>
                  <lpage>152</lpage>
                  <pub-id pub-id-type="doi">10.1159/000488816</pub-id>
                  <?supplied-pmid 29705798?>
                  <pub-id pub-id-type="pmid">29705798</pub-id>
                </element-citation>
              </ref>
              <ref id="B48">
                <label>48</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brennan</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function</article-title>
                  <source>Nat Rev Nephrol</source>
                  <year>2021</year>
                  <volume>17</volume>
                  <issue>11</issue>
                  <fpage>725</fpage>
                  <lpage>739</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41581-021-00454-y</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8287849</pub-id>-->
                  <?supplied-pmid 34282342?>
                  <pub-id pub-id-type="pmid">34282342</pub-id>
                </element-citation>
              </ref>
              <ref id="B49">
                <label>49</label>
                <element-citation publication-type="book">
                  <comment>Vaziri ND, et al. Chapter 4 - Altered lipid metabolism and serum lipids in chronic kidney disease. In: Kopple JD, et al, eds. <italic toggle="yes">Nutritional Management of Renal Disease</italic>. 4th Ed. Academic Press; 2022:43–60.</comment>
                </element-citation>
              </ref>
              <ref id="B50">
                <label>50</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tran</surname>
                      <given-names>MT</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection</article-title>
                  <source>Nature</source>
                  <year>2016</year>
                  <volume>531</volume>
                  <issue>7595</issue>
                  <fpage>528</fpage>
                  <lpage>532</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature17184</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4909121</pub-id>-->
                  <?supplied-pmid 26982719?>
                  <pub-id pub-id-type="pmid">26982719</pub-id>
                </element-citation>
              </ref>
              <ref id="B51">
                <label>51</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hammond</surname>
                      <given-names>LE</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition</article-title>
                  <source>Mol Cell Biol</source>
                  <year>2002</year>
                  <volume>22</volume>
                  <issue>23</issue>
                  <fpage>8204</fpage>
                  <lpage>8214</lpage>
                  <pub-id pub-id-type="doi">10.1128/MCB.22.23.8204-8214.2002</pub-id>
                  <!--<pub-id pub-id-type="pmcid">134068</pub-id>-->
                  <?supplied-pmid 12417724?>
                  <pub-id pub-id-type="pmid">12417724</pub-id>
                </element-citation>
              </ref>
              <ref id="B52">
                <label>52</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mantovani</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease</article-title>
                  <source>Diabetes Metab</source>
                  <year>2021</year>
                  <volume>47</volume>
                  <issue>1</issue>
                  <elocation-id>101152</elocation-id>
                  <pub-id pub-id-type="doi">10.1016/j.diabet.2020.03.003</pub-id>
                  <?supplied-pmid 32283179?>
                  <pub-id pub-id-type="pmid">32283179</pub-id>
                </element-citation>
              </ref>
              <ref id="B53">
                <label>53</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zeng</surname>
                      <given-names>W</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Lipidomic profiling in the strong heart study identified american indians at risk of chronic kidney disease</article-title>
                  <source>Kidney Int</source>
                  <year>2022</year>
                  <volume>102</volume>
                  <issue>22</issue>
                  <fpage>1154</fpage>
                  <lpage>1166</lpage>
                  <?supplied-pmid 35853479?>
                  <pub-id pub-id-type="pmid">35853479</pub-id>
                </element-citation>
              </ref>
              <ref id="B54">
                <label>54</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blachnio-Zabielska</surname>
                      <given-names>AU</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The crucial role of C18-Cer in fat-induced skeletal muscle insulin resistance</article-title>
                  <source>Cell Physiol Biochem</source>
                  <year>2016</year>
                  <volume>40</volume>
                  <issue>5</issue>
                  <fpage>1207</fpage>
                  <lpage>1220</lpage>
                  <pub-id pub-id-type="doi">10.1159/000453174</pub-id>
                  <?supplied-pmid 27960149?>
                  <pub-id pub-id-type="pmid">27960149</pub-id>
                </element-citation>
              </ref>
              <ref id="B55">
                <label>55</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pickersgill</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Key role for ceramides in mediating insulin resistance in human muscle cells</article-title>
                  <source>J Biol Chem</source>
                  <year>2007</year>
                  <volume>282</volume>
                  <issue>17</issue>
                  <fpage>12583</fpage>
                  <lpage>12589</lpage>
                  <pub-id pub-id-type="doi">10.1074/jbc.M611157200</pub-id>
                  <?supplied-pmid 17337731?>
                  <pub-id pub-id-type="pmid">17337731</pub-id>
                </element-citation>
              </ref>
              <ref id="B56">
                <label>56</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Turpin</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance</article-title>
                  <source>Am J Physiol Endocrinol Metab</source>
                  <year>2006</year>
                  <volume>291</volume>
                  <issue>6</issue>
                  <fpage>E1341</fpage>
                  <lpage>E1350</lpage>
                  <pub-id pub-id-type="doi">10.1152/ajpendo.00095.2006</pub-id>
                  <?supplied-pmid 16849630?>
                  <pub-id pub-id-type="pmid">16849630</pub-id>
                </element-citation>
              </ref>
              <ref id="B57">
                <label>57</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huynh</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>High-Throughput plasma lipidomics: detailed mapping of the associations with cardiometabolic risk factors</article-title>
                  <source>Cell Chem Biol</source>
                  <year>2019</year>
                  <volume>26</volume>
                  <issue>1</issue>
                  <fpage>71</fpage>
                  <lpage>84.e4</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.chembiol.2018.10.008</pub-id>
                  <?supplied-pmid 30415965?>
                  <pub-id pub-id-type="pmid">30415965</pub-id>
                </element-citation>
              </ref>
              <ref id="B58">
                <label>58</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhao</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus</article-title>
                  <source>BMC Med Genomics</source>
                  <year>2013</year>
                  <volume>6 suppl 1</volume>
                  <issue>suppl 1</issue>
                  <elocation-id>S12</elocation-id>
                  <!--<pub-id pub-id-type="pmcid">3552685</pub-id>-->
                  <?supplied-pmid 23369247?>
                  <pub-id pub-id-type="pmid">23369247</pub-id>
                </element-citation>
              </ref>
              <ref id="B59">
                <label>59</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Calzada</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Phosphatidylethanolamine metabolism in health and disease</article-title>
                  <source>Int Rev Cell Mol Biol</source>
                  <year>2016</year>
                  <volume>321</volume>
                  <fpage>29</fpage>
                  <lpage>88</lpage>
                  <pub-id pub-id-type="doi">10.1016/bs.ircmb.2015.10.001</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4778737</pub-id>-->
                  <?supplied-pmid 26811286?>
                  <pub-id pub-id-type="pmid">26811286</pub-id>
                </element-citation>
              </ref>
              <ref id="B60">
                <label>60</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Houtkooper</surname>
                      <given-names>RH</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Sirtuins as regulators of metabolism and healthspan</article-title>
                  <source>Nat Rev Mol Cell Biol</source>
                  <year>2012</year>
                  <volume>13</volume>
                  <issue>4</issue>
                  <fpage>225</fpage>
                  <lpage>238</lpage>
                  <!--<pub-id pub-id-type="pmcid">4872805</pub-id>-->
                  <?supplied-pmid 22395773?>
                  <pub-id pub-id-type="pmid">22395773</pub-id>
                </element-citation>
              </ref>
              <ref id="B61">
                <label>61</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mallamaci</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Physical activity in chronic kidney disease and the EXerCise introduction to enhance trial</article-title>
                  <source>Nephrol Dial Transplant</source>
                  <year>2020</year>
                  <volume>35</volume>
                  <issue>suppl 2</issue>
                  <fpage>ii18</fpage>
                  <lpage>ii22</lpage>
                  <!--<pub-id pub-id-type="pmcid">7066543</pub-id>-->
                  <?supplied-pmid 32162664?>
                  <pub-id pub-id-type="pmid">32162664</pub-id>
                </element-citation>
              </ref>
              <ref id="B62">
                <label>62</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cooke</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effects of acute and 14-day coenzyme Q10 supplementation on exercise performance in both trained and untrained individuals</article-title>
                  <source>J Int Soc Sports Nutr</source>
                  <year>2008</year>
                  <volume>5</volume>
                  <issue>1</issue>
                  <elocation-id>8</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/1550-2783-5-8</pub-id>
                  <!--<pub-id pub-id-type="pmcid">2315638</pub-id>-->
                  <?supplied-pmid 18318910?>
                  <pub-id pub-id-type="pmid">18318910</pub-id>
                </element-citation>
              </ref>
              <ref id="B63">
                <label>63</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aoike</surname>
                      <given-names>DT</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Impact of home-based aerobic exercise on the physical capacity of overweight patients with chronic kidney disease</article-title>
                  <source>Int Urol Nephrol</source>
                  <year>2015</year>
                  <volume>47</volume>
                  <issue>2</issue>
                  <fpage>359</fpage>
                  <lpage>367</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11255-014-0894-8</pub-id>
                  <?supplied-pmid 25503447?>
                  <pub-id pub-id-type="pmid">25503447</pub-id>
                </element-citation>
              </ref>
              <ref id="B64">
                <label>64</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirkman</surname>
                      <given-names>DL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A randomized trial of aerobic exercise in chronic kidney disease: evidence for blunted cardiopulmonary adaptations</article-title>
                  <source>Ann Phys Rehabil Med</source>
                  <year>2021</year>
                  <volume>64</volume>
                  <issue>6</issue>
                  <elocation-id>101469</elocation-id>
                  <pub-id pub-id-type="doi">10.1016/j.rehab.2020.101469</pub-id>
                  <!--<pub-id pub-id-type="pmcid">8943710</pub-id>-->
                  <?supplied-pmid 33316435?>
                  <pub-id pub-id-type="pmid">33316435</pub-id>
                </element-citation>
              </ref>
              <ref id="B65">
                <label>65</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Merry</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Ristow</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Mitohormesis in exercise training</article-title>
                  <source>Free Radic Biol Med</source>
                  <year>2016</year>
                  <volume>98</volume>
                  <fpage>123</fpage>
                  <lpage>130</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.11.032</pub-id>
                  <?supplied-pmid 26654757?>
                  <pub-id pub-id-type="pmid">26654757</pub-id>
                </element-citation>
              </ref>
              <ref id="B66">
                <label>66</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cantó</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>NAD(+) Metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus</article-title>
                  <source>Cell Metab</source>
                  <year>2015</year>
                  <volume>22</volume>
                  <issue>1</issue>
                  <fpage>31</fpage>
                  <lpage>53</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cmet.2015.05.023</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4487780</pub-id>-->
                  <?supplied-pmid 26118927?>
                  <pub-id pub-id-type="pmid">26118927</pub-id>
                </element-citation>
              </ref>
              <ref id="B67">
                <label>67</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Palmeira</surname>
                      <given-names>CM</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Mitohormesis and metabolic health: The interplay between ROS, cAMP and sirtuins</article-title>
                  <source>Free Radic Biol Med</source>
                  <year>2019</year>
                  <volume>141</volume>
                  <fpage>483</fpage>
                  <lpage>491</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.07.017</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6718302</pub-id>-->
                  <?supplied-pmid 31349039?>
                  <pub-id pub-id-type="pmid">31349039</pub-id>
                </element-citation>
              </ref>
              <ref id="B68">
                <label>68</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nishida</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Astaxanthin stimulates mitochondrial biogenesis in insulin resistant muscle via activation of AMPK pathway</article-title>
                  <source>J Cachexia Sarcopenia Muscle</source>
                  <year>2020</year>
                  <volume>11</volume>
                  <issue>1</issue>
                  <fpage>241</fpage>
                  <lpage>258</lpage>
                  <pub-id pub-id-type="doi">10.1002/jcsm.12530</pub-id>
                  <!--<pub-id pub-id-type="pmcid">7015247</pub-id>-->
                  <?supplied-pmid 32003547?>
                  <pub-id pub-id-type="pmid">32003547</pub-id>
                </element-citation>
              </ref>
              <ref id="B69">
                <label>69</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>SZ</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Building strength, endurance, and mobility using an astaxanthin formulation with functional training in elderly</article-title>
                  <source>J Cachexia Sarcopenia Muscle</source>
                  <year>2018</year>
                  <volume>9</volume>
                  <issue>5</issue>
                  <fpage>826</fpage>
                  <lpage>833</lpage>
                  <pub-id pub-id-type="doi">10.1002/jcsm.12318</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6204600</pub-id>-->
                  <?supplied-pmid 30259703?>
                  <pub-id pub-id-type="pmid">30259703</pub-id>
                </element-citation>
              </ref>
              <ref id="B70">
                <label>70</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Martens</surname>
                      <given-names>CR</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD<sup>+</sup> in healthy middle-aged and older adults</article-title>
                  <source>Nat Commun</source>
                  <year>2018</year>
                  <volume>9</volume>
                  <issue>1</issue>
                  <elocation-id>1286</elocation-id>
                  <pub-id pub-id-type="doi">10.1038/s41467-018-03421-7</pub-id>
                  <!--<pub-id pub-id-type="pmcid">5876407</pub-id>-->
                  <?supplied-pmid 29599478?>
                  <pub-id pub-id-type="pmid">29599478</pub-id>
                </element-citation>
              </ref>
              <ref id="B71">
                <label>71</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yeung</surname>
                      <given-names>CK</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress</article-title>
                  <source>BMC Nephrol</source>
                  <year>2015</year>
                  <volume>16</volume>
                  <elocation-id>183</elocation-id>
                  <pub-id pub-id-type="doi">10.1186/s12882-015-0178-2</pub-id>
                  <!--<pub-id pub-id-type="pmcid">4630830</pub-id>-->
                  <?supplied-pmid 26531095?>
                  <pub-id pub-id-type="pmid">26531095</pub-id>
                </element-citation>
              </ref>
              <ref id="B72">
                <label>72</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Graf</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>The Lawton instrumental activities of daily living scale</article-title>
                  <source>Am J Nurs</source>
                  <year>2008</year>
                  <volume>108</volume>
                  <issue>4</issue>
                  <fpage>52-62; quiz 62</fpage>
                  <lpage>quiz 63</lpage>
                  <pub-id pub-id-type="doi">10.1097/01.NAJ.0000314810.46029.74</pub-id>
                  <?supplied-pmid 18367931?>
                  <pub-id pub-id-type="pmid">18367931</pub-id>
                </element-citation>
              </ref>
              <ref id="B73">
                <label>73</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Howley</surname>
                      <given-names>ET</given-names>
                    </name>
                    <name>
                      <surname>Bassett</surname>
                      <given-names>DR</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Welch</surname>
                      <given-names>HG</given-names>
                    </name>
                  </person-group>
                  <article-title>Criteria for maximal oxygen uptake: review and commentary</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>1995</year>
                  <volume>27</volume>
                  <issue>9</issue>
                  <fpage>1292</fpage>
                  <lpage>1301</lpage>
                  <?supplied-pmid 8531628?>
                  <pub-id pub-id-type="pmid">8531628</pub-id>
                </element-citation>
              </ref>
              <ref id="B74">
                <label>74</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wagner</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>New Data-based cutoffs for maximal exercise criteria across the lifespan</article-title>
                  <source>Med Sci Sports Exerc</source>
                  <year>2020</year>
                  <volume>52</volume>
                  <issue>9</issue>
                  <fpage>1915</fpage>
                  <lpage>1923</lpage>
                  <pub-id pub-id-type="doi">10.1249/MSS.0000000000002344</pub-id>
                  <?supplied-pmid 32224715?>
                  <pub-id pub-id-type="pmid">32224715</pub-id>
                </element-citation>
              </ref>
              <ref id="B75">
                <label>75</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Forest</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Comprehensive and reproducible untargeted lipidomic workflow using LC-QTOF validated for human plasma analysis</article-title>
                  <source>J Proteome Res</source>
                  <year>2018</year>
                  <volume>17</volume>
                  <issue>11</issue>
                  <fpage>3657</fpage>
                  <lpage>3670</lpage>
                  <pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00270</pub-id>
                  <!--<pub-id pub-id-type="pmcid">6572761</pub-id>-->
                  <?supplied-pmid 30256116?>
                  <pub-id pub-id-type="pmid">30256116</pub-id>
                </element-citation>
              </ref>
              <ref id="B76">
                <label>76</label>
                <element-citation publication-type="book">
                  <comment>Cajka T. Chapter 12 - gas chromatography–time-of-flight mass spectrometry in food and environmental analysis. In: Ferrer I, Thurman EM, eds. <italic toggle="yes">Comprehensive Analytical Chemistry</italic>. Elsevier; 2013:271–302.</comment>
                </element-citation>
              </ref>
              <ref id="B77">
                <label>77</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Piercy</surname>
                      <given-names>KL</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>The physical activity guidelines for Americans</article-title>
                  <source>JAMA</source>
                  <year>2018</year>
                  <volume>320</volume>
                  <issue>19</issue>
                  <fpage>2020</fpage>
                  <lpage>2028</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2018.14854</pub-id>
                  <!--<pub-id pub-id-type="pmcid">9582631</pub-id>-->
                  <?supplied-pmid 30418471?>
                  <pub-id pub-id-type="pmid">30418471</pub-id>
                </element-citation>
              </ref>
              <ref id="B78">
                <label>78</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fan</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Systematic Error removal using random forest for normalizing large-scale untargeted lipidomics data</article-title>
                  <source>Anal Chem</source>
                  <year>2019</year>
                  <volume>91</volume>
                  <issue>5</issue>
                  <fpage>3590</fpage>
                  <lpage>3596</lpage>
                  <pub-id pub-id-type="doi">10.1021/acs.analchem.8b05592</pub-id>
                  <!--<pub-id pub-id-type="pmcid">9652764</pub-id>-->
                  <?supplied-pmid 30758187?>
                  <pub-id pub-id-type="pmid">30758187</pub-id>
                </element-citation>
              </ref>
              <ref id="B79">
                <label>79</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Faraone</surname>
                      <given-names>SV</given-names>
                    </name>
                  </person-group>
                  <article-title>Interpreting estimates of treatment effects: implications for managed care</article-title>
                  <source>P T</source>
                  <year>2008</year>
                  <volume>33</volume>
                  <issue>12</issue>
                  <fpage>700</fpage>
                  <lpage>711</lpage>
                  <!--<pub-id pub-id-type="pmcid">2730804</pub-id>-->
                  <?supplied-pmid 19750051?>
                  <pub-id pub-id-type="pmid">19750051</pub-id>
                </element-citation>
              </ref>
              <ref id="B80">
                <label>80</label>
                <element-citation publication-type="webpage" publication-format="online">
                  <comment>R: A language and environment for statistical computing. Version 4.3.0. R Foundation for Statistical Computing; 2023. <ext-link xlink:href="https://www.R-project.org/" ext-link-type="uri">https://www.R-project.org/</ext-link></comment>
                </element-citation>
              </ref>
              <ref id="B81">
                <label>81</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Greenwood</surname>
                      <given-names>SA</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial</article-title>
                  <source>Am J Kidney Dis</source>
                  <year>2015</year>
                  <volume>65</volume>
                  <issue>3</issue>
                  <fpage>425</fpage>
                  <lpage>434</lpage>
                  <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.07.015</pub-id>
                  <?supplied-pmid 25236582?>
                  <pub-id pub-id-type="pmid">25236582</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <notes notes-type="version-changes">
              <sec sec-type="version-changes">
                <label>Version 1</label>
                <title>05/09/2023</title>
                <p>In-Press Preview</p>
              </sec>
              <sec sec-type="version-changes">
                <label>Version 2</label>
                <title>06/08/2023</title>
                <p>Electronic publication</p>
              </sec>
              <sec sec-type="version-changes">
                <label>Version 3</label>
                <title>06/27/2023</title>
                <p>The last paragraph of the Results section contained a typo. It is fixed now</p>
              </sec>
            </notes>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Figure 1</label>
              <caption>
                <title>No changes in physical endurance and CRF outcomes after NR and CoQ10 treatments compared with placebo (<italic toggle="yes">n</italic> = 25).</title>
                <p>(<bold>A</bold>) VO<sub>2</sub> peak, (<bold>B</bold> and <bold>C</bold>) absolute VO<sub>2</sub> at 30 and 60 W, (<bold>D</bold>) test duration, (<bold>E</bold>) total work, and (<bold>F</bold>) total work efficiency. Two-way ANOVA was used to compare changes in response to NR and CoQ10 with placebo. The box plots represent median and IQR and the whiskers represent minimum and maximum values. *<italic toggle="yes">P</italic> &lt; 0.05. NS, not significant.</p>
              </caption>
              <graphic xlink:href="jciinsight-8-167274-g294" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Figure 2</label>
              <caption>
                <title>Heatmap depicting compositional changes within lipid classes in response to NR and CoQ10 supplementation.</title>
                <p>The colors of the heatmap are based on effect size obtained from linear mixed effects modeling adjusted for fasting status. *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.001. The lipid classes include fatty acyls (fatty acids), glycerolipids (triglycerides and diacylglycerols), glycerophospholipids (PEs, LPEs, LPCs, and PCs), sphingolipids (ceramides and glycosylceramides), steroids, and steroid lipids (cholesterol and cholesteryl ester).</p>
              </caption>
              <graphic xlink:href="jciinsight-8-167274-g295" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <title>Participant characteristics of analytic population</title>
              </caption>
              <graphic xlink:href="jciinsight-8-167274-g296" position="float"/>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2</label>
              <caption>
                <title>Summary of primary and exploratory physical endurance outcomes comparing NR and CoQ10 with placebo</title>
              </caption>
              <graphic xlink:href="jciinsight-8-167274-g297" position="float"/>
            </table-wrap>
            <table-wrap position="float" id="T3">
              <label>Table 3</label>
              <caption>
                <title>The impact of NR supplementation on plasma metabolites compared with placebo</title>
              </caption>
              <graphic xlink:href="jciinsight-8-167274-g298" position="float"/>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
